2.330CADMkt Cap: 5.95M CADP/E: —Last update: 2026-05-21
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops precision medicines addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kin…
Industry Peers
Biotechnologyloading…
Indicators:|
Key Statistics
Company
Market Cap5.95M CAD
Enterprise Value37.88M CAD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-25.47M CAD
Revenue/Share—
Last Price2.330 CAD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees14
CountryCA
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.76
PEG—
EV/EBITDA-1.43
EV/Revenue—
P/S—
P/B-0.12
EPS (TTM)-14.31
EPS (Forward)-3.05
52W Range
—
52W High2.330 CAD
52W Low2.330 CAD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE93.75%
ROA-254.37%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-21.99M CAD
CapEx (TTM)—
FCF Margin—
FCF Yield-241.53%
Net Debt31.93M CAD
Net Debt/EBITDA-1.21
Balance Sheet
Debt/Equity-1.03
Current Ratio0.55
Quick Ratio0.09
Book Value/Sh-18.6961 CAD
Cash/Share0.4000 CAD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 CAD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:15
Split DateJun 6, 2023
Analyst Consensus
Rating—
Target (Mean)2.356 CAD
Target Range2.356 CAD – 2.356 CAD
# Analysts1
Ownership
Shares Out.2.55M
Float1.86M
Insiders27.37%
Institutions3.91%
Short Interest
Short Ratio0.1d
Short % Float0.02%
Short % Out.0.01%
Shares Short378
Short (prev mo.)1.23K
Technical
SMA 502.288 (+1.8%)
SMA 2002.053 (+13.5%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)153
Avg Vol (10d)1.28K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—